Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the rectum~  * Locally advanced (T3-4 Nx) or metastatic (T2 N+ M1) synchronous disease~    * Metastases must be resectable~ * Primary tumor examined by endorectal echography and MRI~* Measurable disease by thoraco-abdomino-pelvic scanner~* Disease considered susceptible to treatment with radiotherapy and chemotherapy~* No diffuse metastases considered nonresectable~* No acute occlusion not caused by colostomy~PATIENT CHARACTERISTICS:~Inclusion criteria:~* ECOG performance status 0-2~* WBC ≥ 4,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~* Creatinine ≤ 130 µmol/L~* Transaminases ≤ 5 times upper limit of normal (ULN)~* Total bilirubin ≤ 1.5 times ULN~* Alkaline phosphatase ≤ 2.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients of must use effective contraception~Exclusion criteria:~* Contraindication to therapy with capecitabine, oxaliplatin, cetuximab, and/or radiotherapy~* Impossible to perform translational analyses~* Uncontrolled severe illness~* Severe renal or hepatic insufficiency~* Cardiac insufficiency or symptomatic coronary disease~* Sensitive peripheral neuropathy~* Uncontrolled diabetes~* Other malignancy within the past 10 years except previously treated basal cell skin cancer or carcinoma in situ of the cervix~* Impossible to participate in study due to geographic, social, or psychiatric reasons~* Patients who are under supervision or incarcerated~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior anticancer chemotherapy or radiotherapy for this cancer~* No therapy with coumarin anticoagulants, phenytoin, sorivudine, brivudine, antacids, or allopurinol~* No concurrent participation in another therapeutic study or receiving another experimental drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).